This review summarizes the current evidence for the management of pulmonary thromboembolism, focusing on anticoagulation duration and the use of NOACs versus warfarin.
May guide VTE anticoagulation choices; leaves open need for updated RCTs on duration and NOAC optimization.
The incidence of venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE) is increasing in Korea. In addition, awareness of VTE according to the incidence is improving, but how long VTE should be treated and how effective VTE patients should be managed with warfarin is not well defined. Recently, various new oral anticoagulants (NOACs) were introduced in clinical practice. The duration of anticoagulation, quality control of warfarin, and practical use of NOACs in VTE would be reviewed with evidences. (Korean J Med 2013;84:659-669)
No takes yet. Share an insight, caveat, or question.
Yang‐Ki Kim (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: